Insight into the molecular mechanisms of gastric cancer stem cell in drug resistance of gastric cancer

Abstract

Gastric cancer (GC) is one of the most common causes of cancer-related death worldwide, and gastric cancer stem cells (GCSCs) are considered as the major factor for resistance to conventional radio- and chemotherapy. Accumulating evidence in recent years implies that GCSCs regulate the drug resistance in GC through multiple mechanisms, including dormancy, drug trafficking, drug metabolism and targeting, apoptosis, DNA damage, epithelial-mesenchymal transition, and tumor microenvironment. In this review, we summarize current advancements regarding the relationship between GCSCs and drug resistance and evaluate the molecular bases of GCSCs in drug resistance.

Keywords

Gastric cancer / gastric cancer stem cells / drug resistance / chemotherapy / molecular mechanisms

References

[1] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Lauren P.The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification.Acta Pathol Microbiol Scand1965;64:31-49

[3] Fléjou JF.WHO Classification of digestive tumors: the fourth edition.Ann Pathol2011;31:S27-31

[4] Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma.Nature2014;513:202-9

[5] Cristescu R,Nebozhyn M.Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.Nat Med2015;21:449-56

[6] Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer.Lancet2016;388:2654-64

[7] Jim MA,Carreira H,Wiggins CL.Stomach cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study.Cancer2017;123 Suppl 24:4994-5013 PMCID:PMC5826592

[8] MacDonald JS,Woolley PV.5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.Ann Intern Med1980;93:533-6

[9] Wils JA,Wagener DJ.Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.J Clin Oncol1991;9:827-31

[10] Webb A,Scarffe JH.Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.J Clin Oncol1997;15:261-7

[11] Cutsem E, Moiseyenko VM, Tjulandin S, et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.J Clin Oncol2006;24:4991-7

[12] Cunningham D,Rao S.Upper gastrointestinal clinical studies group of the national cancer research institute of the united kingdomCapecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med2008;358:36-46

[13] Kang YK,Shin DB.Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.Ann Oncol2009;20:666-73

[14] Shah MA,Stoller R.Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US gastric cancer consortium.J Clin Oncol2015;33:3874-9

[15] Koizumi W,Fujii M.JACCRO and KCSG Study GroupAddition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).J Cancer Res Clin Oncol2014;140:319-28 PMCID:PMC3895196

[16] Guimbaud R,Ries P.Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.J Clin Oncol2014;32:3520-6

[17] Li K,Li X,Zhao L.Advances in clinical immunotherapy for gastric cancer.Biochim Biophys Acta Rev Cancer2021;1876:188615

[18] Hsu A.Advances in Systemic Therapy for gastric cancer.Gastrointest Endosc Clin N Am2021;31:607-23

[19] Bang Y,Feyereislova A.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet2010;376:687-97

[20] Shitara K,Iwasa S.DESTINY-Gastric01 InvestigatorsTrastuzumab deruxtecan in previously treated HER2-positive gastric cancer.N Engl J Med2020;382:2419-30

[21] Satoh T,Chung HC.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study.J Clin Oncol2014;32:2039-49

[22] Hecht JR,Qin SK.Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC--a randomized phase III trial.J Clin Oncol2016;34:443-51

[23] Rugo HS,Cardoso F.SOPHIA Study GroupEfficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial.JAMA Oncol2021;7:573-84 PMCID:PMC7823434

[24] Ohtsu A,Van Cutsem E.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.J Clin Oncol2011;29:3968-76

[25] Fuchs CS,Yong CJ.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet2014;383:31-9

[26] Wilke H,Van Cutsem E.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.Lancet Oncol2014;15:1224-35

[27] Li J,Xu J.Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction.J Clin Oncol2016;34:1448-54

[28] Pavlakis N,Martin AJ.Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial.J Clin Oncol2016;34:2728-35 PMCID:PMC5019744

[29] Lordick F,Chung H.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.Lancet Oncol2013;14:490-9

[30] Waddell T,Cunningham D.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.Lancet Oncol2013;14:481-9 PMCID:PMC3669518

[31] Catenacci DVT,Lee J.Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-selected gastroesophageal adenocarcinoma.J Clin Oncol2020;38:2418-26 PMCID:PMC7367551

[32] Ohtsu A,Bai YX.Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.J Clin Oncol2013;31:3935-43 PMCID:PMC5950503

[33] Sahin U,Dhaene K.Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.Clin Cancer Res2008;14:7624-34

[34] Kang Y,Satoh T.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;390:2461-71

[35] Shitara K,Bang YJ.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial.JAMA Oncol2020;6:1571-80

[36] Shitara K,Bang Y.Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.Lancet2018;392:123-33

[37] Kelly RJ,Bang YJ.Safety and Efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma.Clin Cancer Res2020;26:846-54

[38] Bang YJ,Van Cutsem E.Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.Ann Oncol2018;29:2052-60 PMCID:PMC6225815

[39] Bang YJ,Kim YH.Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer.Clin Cancer Res2017;23:5671-8

[40] Marin JJG,Macias RIR.Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma.Cancers (Basel)2020;12:2116 PMCID:PMC7463778

[41] Pützer BM,Herchenröder O.Advances in cancer stem cell targeting: how to strike the evil at its root.Adv Drug Deliv Rev2017;120:89-107

[42] Valent P,De Maria R.Cancer stem cell definitions and terminology: the devil is in the details.Nat Rev Cancer2012;12:767-75

[43] Kreso A.Evolution of the cancer stem cell model.Cell Stem Cell2014;14:275-91

[44] Singh SK,Clarke ID.Identification of human brain tumour initiating cells.Nature2004;432:396-401

[45] Al-Hajj M,Benito-Hernandez A,Clarke MF.Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci USA2003;100:3983-8 PMCID:PMC153034

[46] Prince ME,Kaczorowski A.Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.Proc Natl Acad Sci USA2007;104:973-8 PMCID:PMC1783424

[47] Bussolati B,Azzarone B.Human renal cancer stem cells.Cancer Lett2013;338:141-6

[48] O'Brien CA,Gallinger S.A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.Nature2007;445:106-10

[49] Ricci-Vitiani L,Pilozzi E.Identification and expansion of human colon-cancer-initiating cells.Nature2007;445:111-5

[50] Dalerba P,Park IK.Phenotypic characterization of human colorectal cancer stem cells.Proc Natl Acad Sci USA2007;104:10158-63 PMCID:PMC1891215

[51] Li C,Dalerba P.Identification of pancreatic cancer stem cells.Cancer Res2007;67:1030-7

[52] Hermann PC,Herrler T.Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.Cell Stem Cell2007;1:313-23

[53] Ma S,Hu L.Identification and characterization of tumorigenic liver cancer stem/progenitor cells.Gastroenterology2007;132:2542-56

[54] Lundin A.Lung cancer stem cells: progress and prospects.Cancer Lett2013;338:89-93 PMCID:PMC3686996

[55] Collins AT,Hyde C,Maitland NJ.Prospective identification of tumorigenic prostate cancer stem cells.Cancer Res2005;65:10946-51

[56] Fang D,Leishear K.A tumorigenic subpopulation with stem cell properties in melanomas.Cancer Res2005;65:9328-37

[57] Yang L,Zhao G.Targeting cancer stem cell pathways for cancer therapy.Signal Transduct Target Ther2020;5:8 PMCID:PMC7005297

[58] Xiao W,Duan Y,Ke Y.Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.J Exp Clin Cancer Res2017;36:41 PMCID:PMC5345133

[59] Mohammed MK,Wang J.Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance.Genes Dis2016;3:11-40 PMCID:PMC4827448

[60] Bekaii-Saab T.Identifying and targeting cancer stem cells in the treatment of gastric cancer.Cancer2017;123:1303-12 PMCID:PMC5412889

[61] Matsui WH.Cancer stem cell signaling pathways.Medicine (Baltimore)2016;95:S8-S19 PMCID:PMC5599211

[62] Nunes T,Leboeuf C.Targeting cancer stem cells to overcome chemoresistance.Int J Mol Sci2018;19:4036 PMCID:PMC6321478

[63] Brungs D,Vine KL,Carolan MG.Gastric cancer stem cells: evidence, potential markers, and clinical implications.J Gastroenterol2016;51:313-26

[64] Li Y,Ajani JA.Drug resistance and cancer stem cells.Cell Commun Signal2021;19:19 PMCID:PMC7885480

[65] Takaishi S,Tu S.Identification of gastric cancer stem cells using the cell surface marker CD44.Stem Cells2009;27:1006-20 PMCID:PMC2746367

[66] Qiao XT.Current molecular markers for gastric progenitor cells and gastric cancer stem cells.J Gastroenterol2011;46:855-65

[67] Fu L,Yasuda T.Gastric cancer stem cells: current insights into the immune microenvironment and therapeutic targets.Biomedicines2020;8:7 PMCID:PMC7168269

[68] Ray K.Stem cells: Settling the stomach - tracing gastric stem cells.Nat Rev Gastroenterol Hepatol2016;13:626

[69] Takaishi S,Wang TC.Gastric cancer stem cells.J Clin Oncol2008;26:2876-82 PMCID:PMC2743304

[70] Toledo-Guzmán ME,Gómez-Gallegos ÁA.ALDH as a stem cell marker in solid tumors.Curr Stem Cell Res Ther2019;14:375-88

[71] Zhi QM,Ji J.Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer.Biomed Pharmacother2011;65:509-15

[72] Cojoc M,Muders MH.A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms.Semin Cancer Biol2015;31:16-27

[73] Wang B,Cao Y.LGR5 is a gastric cancer stem cell marker associated with stemness and the EMT SIgnature genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.PLoS One2016;11:e0168904 PMCID:PMC5199039

[74] Zhang L,Zhang D.Upregulated miR-132 in Lgr5⁺ gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway.Mol Carcinog2017;56:2022-34

[75] Xiong J,Chen T.Verteporfin blocks Clusterin which is required for survival of gastric cancer stem cell by modulating HSP90 function.Int J Biol Sci2019;15:312-24 PMCID:PMC6367548

[76] Ukai S,Sakamoto N.Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell.Oncogene2020;39:7265-78

[77] Zhu Z,Li L.Effect of gastric cancer stem cell on gastric cancer invasion, migration and angiogenesis.Int J Med Sci2020;17:2040-51 PMCID:PMC7415381

[78] Shimoda M,Okada Y.Isolation of cancer stem cells by side population method. In: Papaccio G, Desiderio V, editors. Cancer stem cells. New York: Springer; 2018. pp. 49-59.

[79] Tumor initiating potential of side population cells in human gastric cancer.Int J Oncol2009;

[80] Chen W,Chu C.Identification of CD44+ cancer stem cells in human gastric cancer.Hepatogastroenterology2013;60:949-54

[81] Nishikawa S,Hamabe A.Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy.Int J Oncol2013;42:1437-42

[82] Ishigami S,Arigami T.Prognostic impact of CD133 expression in gastric carcinoma.Anticancer Res2010;30:2453-2457. [PMID: 20651407]

[83] Wang T,Shi J.Sequential expression of putative stem cell markers in gastric carcinogenesis.Br J Cancer2011;105:658-65 PMCID:PMC3188930

[84] Wattanawongdon W,Tongtawee T.Co-expression of LGR5 and CD133 cancer stem cell predicts a poor prognosis in patients with gastric cancer.Turk J Gastroenterol2021;32:261-8 PMCID:PMC8975476

[85] Katoh M.Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers.Clin Sci (Lond)2019;133:953-70

[86] Garcia-Mayea Y,Masson F,LLeonart ME.Insights into new mechanisms and models of cancer stem cell multidrug resistance.Semin Cancer Biol2020;60:166-80

[87] Talukdar S,Emdad L,Sarkar D.Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Cancer stem cells. Elsevier; 2019. pp. 43-84.

[88] Chen K,Ling S,Wang J.The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance.Cell Death Dis2021;12:835 PMCID:PMC8418609

[89] Batlle E.Cancer stem cells revisited.Nat Med2017;23:1124-34

[90] Takeishi S.To wake up cancer stem cells, or to let them sleep, that is the question.Cancer Sci2016;107:875-81 PMCID:PMC4946711

[91] Xu ZY,Xie HX.5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells.Int J Biol Sci2015;11:284-94 PMCID:PMC4323368

[92] Jiang YX,Li PA.The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms.Oncogene2017;36:1256-64 PMCID:PMC5340802

[93] Muley H,Rodríguez-Rodríguez R.Drug uptake-based chemoresistance in breast cancer treatment.Biochem Pharmacol2020;177:113959

[94] Zhang L,Zhang L.SLC34A2 regulates miR-25-Gsk3β signaling pathway to affect tumor progression in gastric cancer stem cell-like cells.Mol Carcinog2018;57:440-50

[95] Zhang JX,Gao Y.Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway.Mol Cancer2017;16:18 PMCID:PMC5259972

[96] Wang JQ,Yang Y.ATP-binding cassette (ABC) transporters in cancer: a review of recent updates.J Evid Based Med2021;14:232-56

[97] Li W,Assaraf YG.Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies.Drug Resist Updat2016;27:14-29

[98] Gottesman MM.The role of multidrug resistance efflux pumps in cancer: revisiting a JNCI publication exploring expression of the MDR1 (P-glycoprotein) gene.J Natl Cancer Inst2015;107:djv222 PMCID:PMC4836801

[99] Duan H,Gao Z.Recent advances in drug delivery systems for targeting cancer stem cells.Acta Pharm Sin B2021;11:55-70 PMCID:PMC7838023

[100] Kim JK,Kim H.The molecular mechanisms underlying the therapeutic resistance of cancer stem cells.Arch Pharm Res2015;38:389-401

[101] Moitra K,Dean M.Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development.Clin Pharmacol Ther2011;89:491-502

[102] Pasello M,Scotlandi K.The ABC subfamily A transporters: multifaceted players with incipient potentialities in cancer.Semin Cancer Biol2020;60:57-71

[103] Xu M,Yang H.Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44(+)/Musashi-1(+) gastric cancer stem cells.Cancer Lett2015;369:124-33

[104] Huang W,Luo Q,Luo Q.Genistein-inhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancer.Int J Mol Sci2014;15:3432-43 PMCID:PMC3975346

[105] Normanno N,Bianco C.Epidermal growth factor receptor (EGFR) signaling in cancer.Gene2006;366:2-16

[106] Martinelli E,Troiani T.Cancer resistance to therapies against the EGFR-RAS-RAF pathway: the role of MEK.Cancer Treat Rev2017;53:61-9

[107] Jo JH,Park S.Novel gastric cancer stem cell-related marker LINGO2 is associated with cancer cell phenotype and patient outcome.Int J Mol Sci2019;20:555 PMCID:PMC6387145

[108] Lee SD,Lee DY,Jo JH.Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells.Cancer Sci2019;110:662-73 PMCID:PMC6361556

[109] Zhu M,Du Y.miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.Mol Med Rep2016;14:1742-50

[110] Du Y,Zhou X.miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB.Tumour Biol2016;37:1261-9

[111] Shao Q,Guan X.In vitro and in vivo effects of miRNA-19b/20a/92a on gastric cancer stem cells and the related mechanism.Int J Med Sci2018;15:86-94 PMCID:PMC5765743

[112] Ishimoto T,Yae T.CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth.Cancer Cell2011;19:387-400

[113] Muzio G,Paiuzzi E,Canuto RA.Aldehyde dehydrogenases and cell proliferation.Free Radic Biol Med2012;52:735-46

[114] Wu D,Chen K.Aldehyde dehydrogenase 3A1 is robustly upregulated in gastric cancer stem-like cells and associated with tumorigenesis.Int J Oncol2016;49:611-22

[115] Ikeda J,Tian T.Reactive oxygen species and aldehyde dehydrogenase activity in Hodgkin lymphoma cells.Lab Invest2012;92:606-14

[116] Aponte PM.Stemness in cancer: stem cells, cancer stem cells, and their microenvironment.Stem Cells Int2017;2017:5619472 PMCID:PMC5394399

[117] Gasparetto M.ALDHs in normal and malignant hematopoietic cells: potential new avenues for treatment of AML and other blood cancers.Chem Biol Interact2017;276:46-51

[118] Nieto MA,Jackson RA.EMT: 2016.Cell2016;166:21-45

[119] Chen T,Jiang H.Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis.J Cell Physiol2017;232:3261-72 PMCID:PMC5507753

[120] Stemmler MP,Brabletz S.Non-redundant functions of EMT transcription factors.Nat Cell Biol2019;21:102-12

[121] Kalluri R.The basics of epithelial-mesenchymal transition.J Clin Invest2009;119:1420-8 PMCID:PMC2689101

[122] Eun K,Kim H.Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting.BMB Rep2017;50:117-25 PMCID:PMC5422023

[123] Dongre A.New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.Nat Rev Mol Cell Biol2019;20:69-84

[124] Shibue T.EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.Nat Rev Clin Oncol2017;14:611-29 PMCID:PMC5720366

[125] Wilson MM,Lees JA.Emerging mechanisms by which EMT programs control stemness.Trends Cancer2020;6:775-80

[126] Singh A.EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.Oncogene2010;29:4741-51 PMCID:PMC3176718

[127] Ma X,Wang X,Fan W.NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.PLoS One2018;13:e0192436 PMCID:PMC5915267

[128] Nassar D.Cancer stem cells: basic concepts and therapeutic implications.Annu Rev Pathol2016;11:47-76

[129] Saygin C,Majeti R,Lathia JD.Targeting cancer stemness in the clinic: from hype to hope.Cell Stem Cell2019;24:25-40

[130] Prager BC,Bao S.Cancer stem cells: the architects of the tumor ecosystem.Cell Stem Cell2019;24:41-53 PMCID:PMC6350931

[131] Fiori ME,Villanova L,Stassi G.Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance.Mol Cancer2019;18:70 PMCID:PMC6441236

[132] Yu Y,Tan LD,Li XQ.Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling.Br J Cancer2014;110:724-32 PMCID:PMC3915130

[133] Choi YJ,Chang H.Helicobacter pylori-induced epithelial-mesenchymal transition, a potential role of gastric cancer initiation and an emergence of stem cells.Carcinogenesis2015;36:553-63

[134] Huang L,Xu AM.Epithelial-mesenchymal transition in gastric cancer.Am J Transl Res2015;7:2141-58. [PMID: 26807164] PMCID:PMC4697696

[135] Han ME,Shin DH,Kang CD.Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells.J Gastroenterol2015;50:645-56

[136] Loeffler M,Niethammer AG.Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.J Clin Invest2006;116:1955-62 PMCID:PMC1481657

[137] Ma Y,Chen S.Low expression of SPARC in gastric cancer-associated fibroblasts leads to stemness transformation and 5-fluorouracil resistance in gastric cancer.Cancer Cell Int2019;19:137 PMCID:PMC6528188

[138] Pegtel DM.Exosomes.Annu Rev Biochem2019;88:487-514

[139] Kalluri R.function, and biomedical applications of exosomes.Science2020;367:eaau6977 PMCID:PMC7717626

[140] Kalluri R.The biology and function of exosomes in cancer.J Clin Invest2016;126:1208-15

[141] Tai YL,Hsieh JT.Exosomes in cancer development and clinical applications.Cancer Sci2018;109:2364-74 PMCID:PMC6113508

[142] Dai J,Zhong S.Exosomes: key players in cancer and potential therapeutic strategy.Signal Transduct Target Ther2020;5:145 PMCID:PMC7406508

[143] Chen G,Zhang W.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.Nature2018;560:382-6 PMCID:PMC6095740

[144] Poggio M,Pai CC.Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory.Cell2019;177:414-427.e13 PMCID:PMC6499401

[145] Wang X,Chen L.Chemotherapeutic drugs stimulate the release and recycling of extracellular vesicles to assist cancer cells in developing an urgent chemoresistance.Mol Cancer2019;18:182 PMCID:PMC6907227

[146] Wu S,To KKW.Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.Mol Cancer2021;20:17 PMCID:PMC7812728

[147] Wang J,Zhao M.Exosome-based cancer therapy: implication for targeting cancer stem cells.Front Pharmacol2016;7:533 PMCID:PMC5226951

[148] Lee NK,Kothandan S,Hwang SR.Exosomes and cancer stem cells in cancer immunity: current reports and future directions.Vaccines (Basel)2021;9:441 PMCID:PMC8147426

[149] Zuo S,Wang C.Extrachromosomal circular DNA (eccDNA): from chaos to function.Front Cell Dev Biol2021;9:792555 PMCID:PMC8785647

[150] Wang M,Yu F,Zhang Y.Extrachromosomal circular DNAs: origin, formation and emerging function in cancer.Int J Biol Sci2021;17:1010-25 PMCID:PMC8040306

[151] Paulsen T,Koseoglu MM.Discoveries of extrachromosomal circles of DNA in normal and tumor cells.Trends Genet2018;34:270-8 PMCID:PMC5881399

[152] Ling X,Meng J.Small extrachromosomal circular DNA (eccDNA): major functions in evolution and cancer.Mol Cancer2021;20:113 PMCID:PMC8414719

[153] Curt GA,Cowan KH.Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes.N Engl J Med1983;308:199-202

[154] Ruiz JC,von Hoff DD,Wahl GM.Autonomously replicating episomes contain mdr1 genes in a multidrug-resistant human cell line.Mol Cell Biol1989;9:109-15 PMCID:PMC362151

[155] Nathanson DA,Mottahedeh J.Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.Science2014;343:72-6 PMCID:PMC4049335

[156] Nikolaev S,Garieri M.Extrachromosomal driver mutations in glioblastoma and low-grade glioma.Nat Commun2014;5:5690 PMCID:PMC4338529

[157] Cai M,Hou L.Inhibiting homologous recombination decreases extrachromosomal amplification but has no effect on intrachromosomal amplification in methotrexate-resistant colon cancer cells.Int J Cancer2019;144:1037-48 PMCID:PMC6586039

[158] Parsonnet J.Gastric adenocarcinoma and Helicobacter pylori infection.West J Med1994;161:60 PMCID:PMC1011373

[159] Lin L,Yi J.Chronic CagA-positive Helicobacter pylori infection with MNNG stimulation synergistically induces mesenchymal and cancer stem cell-like properties in gastric mucosal epithelial cells.J Cell Biochem2019;120:17635-49

[160] Song X,Wang W.Wnt/β-catenin, an oncogenic pathway targeted by H. pylori in gastric carcinogenesis.Oncotarget2015;6:35579-88 PMCID:PMC4742126

[161] Courtois S,Bodineau C.Autophagy induced by Helicobacter pylori infection is necessary for gastric cancer stem cell emergence.Gastric Cancer2021;24:133-44

[162] Tiffon C,Molina-Castro SE.TAZ controls helicobacter pylori-induced epithelial-mesenchymal transition and cancer stem cell-like invasive and tumorigenic properties.Cells2020;9:1462 PMCID:PMC7348942

[163] Oh JD,Gordon JI.Intracellular Helicobacter pylori in gastric epithelial progenitors.Proc Natl Acad Sci USA2005;102:5186-91 PMCID:PMC555607

[164] Giannakis M,Karam SM,Gordon JI.Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells.Proc Natl Acad Sci USA2008;105:4358-63 PMCID:PMC2393758

[165] Varon C,Mazurier F.Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice.Gastroenterology2012;142:281-91

[166] Korkaya H,Charafe-Jauffret E.Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.PLoS Biol2009;7:e1000121 PMCID:PMC2683567

[167] Liu S,Mantle ID.Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells.Cancer Res2006;66:6063-71 PMCID:PMC4386278

[168] Iliopoulos D,Struhl K.An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.Cell2009;139:693-706 PMCID:PMC2783826